Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Clinical Microbiology Reviews
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
ARTICLE

Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology

Rhoda L. Ashley, Anna Wald
Rhoda L. Ashley
Departments of Laboratory Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Wald
Medicine, and
Epidemiology, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CMR.12.1.1
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

SUMMARY

SUMMARY Prevention of genital herpes simplex virus (HSV) infections is desirable from both a public health standpoint and the patient’s perspective. A key factor in the spread of genital herpes infections is the high proportion of undiagnosed infections. Persons with subclinical or unrecognized infections are best diagnosed by accurate, type-specific antibody tests. Unfortunately, these tests are only now becoming widely available. The use of current, conventional (non-type-specific) serologic tests for diagnosis of herpes infections has resulted in confusion and misdiagnosis of patients. This review provides recent information on the epidemiology of genital herpes infections, describes the importance of subclinical herpes infection and shedding, summarizes the status of HSV type-specific serologic assays being developed, and provides indications for using such assays.

EPIDEMIOLOGY OF GENITAL HERPES

Seroprevalence of HSV-2Herpes simplex virus type 2 (HSV-2) is the most common cause of genital ulcers in industrialized countries (22). Serosurveys for type-specific antibodies have shown an increase of over 30% in the prevalence of HSV-2 infections over the past two decades (11, 30, 31). Currently, the prevalence of HSV-2 is greater than 20% among adults in the United States (30). Among white persons in the recent National Health and Nutrition Study (NHANES III), 15% of men and 20% of women were HSV-2 seropositive. Among black persons tested in this study, 35% of men and 55% of women were HSV-2 seropositive. HSV-2 seroprevalence can be as high as 50% among women attending sexually transmitted disease (STD) clinics in the United States, the United Kingdom, or Australia (26, 27, 43). Between 60 and 90% of female commercial sex workers worldwide have antibodies to HSV-2 (25).

Recent Changes in HSV-2 IncidenceWhile studies of HSV-2 incidence suggest that most infections are acquired in the third decade of life (21), the recent seroprevalence studies point to a disturbing shift toward earlier acquisition of HSV-2. For example among teenagers, HSV-2 prevalence is over 5% (4.5% among white persons and 9% among black persons) (30). Serosurveys of a subset of young people, i.e., college students, reveal a similar HSV-2 seroprevalence (1 to 9%) with high yearly seroconversion rates (15, 33). Most troubling, HSV-2 seroprevalence has quintupled in white teenagers and has doubled among young adults in their 20s over the past two decades (30).

Genital HSV-1 InfectionsMost recurrent genital herpes outbreaks are caused by HSV-2. However, it is important to note that an increasing proportion of first episodes are caused by HSV-1. In Seattle and areas of the United Kingdom, this proportion is 30% or more (65, 70). While primary HSV-1 genital infections are clinically indistinguishable from primary episodes caused by HSV-2, the recurrence rate of HSV-1 infection appears to be lower (24). Since type-specific serologic assays for HSV do not distinguish between oral and genital infections, HSV-2 seroprevalence data underestimate the total disease burden of genital herpes infections.

CLINICAL IMPACT OF GENITAL HERPES

Immunocompetent AdultsGenital herpes infections can be associated with serious morbidity. For some adults, particularly those without prior antibodies to either HSV-1 or HSV-2, acquisition of primary genital herpes can cause painful ulcerative lesions and systemic manifestations, including headache, malaise, and fever lasting up to 3 weeks. Meningitis accompanies these symptoms in 10% of men and up to 30% of women with primary infections (24). “Nonprimary first episodes” of HSV-2 genital herpes occur in persons with antibodies to HSV-1. This partial immunity results in milder episodes with lower frequency of constitutional signs and symptoms and shorter duration of lesions. Following the initial genital infection, HSV becomes latent in the sacral nerve ganglia and can reactivate to cause recurrent genital lesions. Approximately 85% of women and nearly all men with symptomatic acquisition of genital HSV-2 infection will have a recurrence within the first year at an average rate of 4 to 5 episodes per year (12). While recurrent episodes are shorter and more localized than first episodes, the chronic nature of this disease and the unpredictable occurrence of recurrences result in persistent psychosocial or psychosexual distress for many patients (20, 34).

Immunosuppressed PatientsPatients undergoing chemotherapy, organ or bone marrow transplant recipients, and patients with human immunodeficiency virus (HIV) infection who experience first or recurrent HSV-1 or HSV-2 episodes can develop severe and extensive lesions, which may become difficult to control by standard antiviral therapy (40, 66, 73). In some cases, visceral spread occurs (41, 45, 73).

NeonatesThe most severely affected population is neonates, who acquire HSV infection after exposure to the virus during birth (84). This is a relatively rare infection, occurring in about 1 in 3,000 births in the northwestern United States and with a somewhat lower frequency in other areas. However, these infections result in permanent neurological damage for many infants despite appropriate antiviral therapy. The increasing acquisition rate of genital herpes among women of childbearing age (30) suggests that more neonates may be exposed to the virus than in past decades.

HSV and HIV-1 InfectionGenital herpes increases the risk of acquisition of HIV-1 as a result of breaks in the genital mucosal barrier and the recruitment of CD4+ lymphocytes into areas of HSV replication (38, 39, 72). Transmission of HIV-1 to sexual partners may also be aided by the presence of genital ulcers. High levels of HIV-1 have been documented in HSV lesions (68). Furthermore HSV reactivates more frequently in persons with HIV-1 infection (69). These findings indicate a higher risk of HIV-1 exposure for individuals whose sexual partners have both HIV-1 and genital herpes infections.

CORRELATES OF GENITAL HERPES INFECTIONS

Demographic and behavioral factors associated with a higher risk of genital herpes infection may be important in selecting candidates for antibody screening tests as they become available. In general, the risk of HSV-2 infection is correlated with markers of increased sexual exposure: early age of first intercourse, larger numbers of lifetime sexual partners, history of other sexually transmitted infections, and increasing age (27, 57, 82). The age-adjusted risk is higher for persons belonging to high-prevalence demographic groups than for middle-class white persons with equal numbers of partners (30, 82). Black persons, individuals from lower socioeconomic groups, and those with poor educational backgrounds have higher rates of genital herpes infection. Those with prior antibodies to HSV-1 are at lower risk than HSV-seronegative individuals of acquiring HSV-2 genital infections; however, this protection is only partial (53).

ROLE OF UNDIAGNOSED INFECTION AND SUBCLINICAL HSV SHEDDING IN THE HERPES EPIDEMIC

Discordance of History and HSV-2-Seropositive StatusNumerous studies have revealed that the majority of HSV-2 infections are undiagnosed. In the large NHANES survey, only 9% of persons with HSV-2 antibodies had knowledge of their disease (30). Conversely, 22% of those denying a history of genital herpes were found to be HSV-2 seropositive. Our studies have found that only 34% of women with HSV-2 antibodies who presented to the Seattle-King County STD Clinic were aware of having genital herpes (43). Among HSV-2-seropositive men and women in a family practice at the University of Washington, only 26% gave a history of genital herpes (58, 82). In the United Kingdom, only 32% of HSV-2-seropositive STD clinic attenders and 17% of HSV-2-seropositive blood donors reported having genital herpes (26).

Asymptomatic and Unrecognized Genital HerpesIt is estimated that about 20% of patients with HSV-2 antibodies are truly asymptomatic or have lesions only in locations, such as the cervix, that are impossible to observe (23). The remaining 60% of undiagnosed persons with genital HSV-2 infection have symptoms that are not recognized by either physicians or patients as being caused by herpes. Atypical manifestations include vulvar, penile, or perianal fissures, localized erythema, and back pain without genital lesions. Both of these groups are at risk of transmitting the virus. However, the majority of patients with atypical, unrecognized symptoms can learn to recognize their own unique manifestations of recurrent episodes (9, 32, 47).

Subclinical Shedding of HSVHSV-2 can reactivate from its latent state in sensory ganglia and cause symptomatic episodes of genital lesions. Nearly all patients with clinically recognized first episodes of HSV-2 have a recurrent episode within a year of acquiring the infection (12). HSV-1 also reactivates in the first year but in only about 55% of patients. Reactivation can also result in subclinical excretion or “shedding” of infectious virus from anogenital sites. Recent studies have shown that recurrent episodes as well as subclinical virus shedding vary in frequency among individuals and, over time, within an individual. Subclinical virus shedding is up to three times more frequent in the first 3 months after acquisition of genital herpes than in later months (42). Subclinical HSV-1 shedding occurs with less than one-third the frequency of HSV-2 shedding. Furthermore, women with frequent clinical recurrences have higher rates of subclinical HSV-2 shedding than do those with infrequent symptomatic recurrences (79).

In established infections, subclinical HSV-2 shedding from the genital tract has been estimated to occur on 1 to 6% of days (10, 16, 42, 64, 79). More intensive studies in which women with recently diagnosed genital HSV-2 infections self-sampled cervical, vulvar, and perianal sites daily for a median of 105 days revealed infectious virus in 75% of the women. The virus was isolated in cell culture of samples obtained on 8% of the days covered by the study (83). In this study, amplification and detection of viral DNA by PCR was shown to be 3.5 times more sensitive than viral isolation in demonstrating HSV in the genital tract. By this technique, HSV was demonstrated in genital secretions in 95% of the women. Overall, women were shedding HSV DNA on 28% of the days sampled (83). Lesions consistent with genital herpes were noted on only 40% of days on which HSV DNA was detected; therefore, most of the viral shedding detected in this study was subclinical.

Data from daily sampling studies suggest that one-half to two-thirds of subclinical HSV shedding episodes occur within a week before or after an episode of clinically recognized, symptomatic HSV shedding (79, 80, 82). Therefore, patients who can be taught to recognize subtle symptoms accompanying HSV reactivation can also recognize at least some of the periods during which they are at higher risk of shedding virus without experiencing symptoms.

While most of the subclinical sampling data have been generated from studies of women, men have been shown to shed HSV asymptomatically from genital sites including intact penile skin (74, 76). Semen can also contain infectious virus, especially during primary HSV infection (56). Infectious virus can be isolated from men on 2.2% of the days sampled, a somewhat lower rate than for women (80).

Transmission of Genital HerpesUnrecognized infections and subclinical viral shedding appear to be major factors in transmission. In a study designed to identify and interview partners of patients with newly diagnosed genital herpes, only 26% of the transmitting partners knew that they were infected (52). The remaining individuals were diagnosed only after they had transmitted herpes to their sexual partner. In a subsequent prospective study of couples where one had genital HSV-2 and the other did not, transmission occurred at an annualized rate of 10%; 70% of the transmission events were during times when the source partner was asymptomatic (53).

Suppressive Antiviral TherapyDaily therapy with oral acyclovir, famciclovir, or valaciclovir reduces the symptomatic recurrence rate (28, 54, 55, 61, 75). Recent studies also suggest that suppressive acyclovir can reduce the frequency of subclinical HSV shedding from the genital tract by as much as 94%. In a blinded crossover study, virus was isolated on 6% of days when women were taking placebo but on fewer than 0.4% of days when they were taking acyclovir (81). HSV-PCR shows that the frequency of genital tract shedding of HSV is reduced by a median 80% (range, 24 to 91%) during acyclovir treatment compared to periods when the subjects were taking a placebo. Viral shedding resumed within 5 days after acyclovir treatment was discontinued (83).

Suppression of clinical and subclinical viral shedding by antiviral therapy may reduce HSV transmission. However, since viral excretion may still occur at low frequency and titer during antiviral therapy, the extent to which antiviral treatment will interrupt transmission remains to be determined.

DIAGNOSIS OF SYMPTOMATIC GENITAL HERPES

Clinical Diagnosis of Genital LesionsClinical presentation, alone, is seldom sufficient to diagnose genital herpes. While some patients present with the classic constellation of bilateral ulcerative lesions, tender inguinal lymphadenopathy, constitutional signs such as fever, and complaints of headache, malaise, and dysuria (24), most do not. Furthermore, genital ulcers or lesions assumed to be caused by herpes may in fact be caused by a number of other infections (syphilis, chancroid, lymphogranuloma venereum, donovanosis, scabies, and candidiasis) or noninfectious conditions (Crohn’s disease, Behçet’s syndrome, trauma, contact dermatitis, erythema multiforme, Reiter’s syndrome, psoriasis, and lichen planus). Microbiologic testing for infectious agents can help ensure that treatable infectious agents are accurately diagnosed.

Equally important, the presenting symptoms of genital herpes are frequently misinterpreted by the patient and by physicians. Skin splits, fissures, minor abrasions, furuncles, erythema, and pain are common manifestations of genital herpes but are often attributed to injury, allergies, insect bites, or other infectious agents (Table1). Clinicians need to have a high index of suspicion for these lesions (44).

View this table:
  • View inline
  • View popup
Table 1.

Patient-reported etiology of genital lesions from which HSV was isolated

However, even the most careful history taken by a practitioner specializing in the care of patients with genital herpes is inadequate to diagnose this disease. In a recent study by Brown et al., a highly experienced clinician conducted a directed interview and then scored the patient as having symptoms “not at all suggestive,” “somewhat suggestive,” or “definitely indicative” of genital herpes (18). Type-specific serology results were then matched with the clinical impression. Consistent with other studies reporting the low sensitivity of history for identifying genital herpes, 37% of those patients with symptoms “not at all suggestive” of herpes were HSV-2 seropositive. Thus, even a highly skilled interview could not elicit a history in a high proportion of infected patients. Moreover, 50% of patients considered to be “highly likely” to be infected were actually HSV-2 seronegative. While a portion of these 50% may have had genital HSV-1 infections, the poor positive predictive value of history for identifying genital herpes confirms the critical role of laboratory methods for diagnosing this disease.

Laboratory Methods for DiagnosisVirus detection methods should be used for patients presenting with lesions. Antigen detection can be nearly as sensitive as culture methods (7), and the most sensitive strategy is to perform both tests. However, the sensitivity of such tests declines as lesions heal and is lower in subjects with recurrent lesions than in those with first episodes (46). Antibody tests are useful as backup tools, particularly when evidence of seroconversion is being sought by type-specific tests.

Role of Serologic TestingDefinitive diagnosis of genital herpes infections is fundamental to the management of patients and the development of strategies to prevent transmission to partners and neonates. Detection of antibodies allows diagnosis of an infection when virological methods such as culture, antigen detection, or PCR are impractical or yield negative results (44). Because HSV-1 and HSV-2 are closely related antigenically and because both viruses cause lifelong infections with intermittent reactivation, the application of serologic testing is more complicated than for many other human viruses. Tests which can identify HSV antibodies but cannot differentiate between HSV-1 and HSV-2 are widely available. As diagnostic tools, these tests are not helpful. For example, if a serologic test is performed to rule out genital herpes in a patient with mild genital symptoms, a positive test could be due to past HSV-1 oral infection. Therefore, definitive tests for HSV-2 antibodies must be based on HSV-2 type-specific antigens.

Inaccuracy of Commercial Tests Based on Whole-Antigen PreparationsIt is important to note that manufacturers of nontyping tests have offered mathematical algorithms to infer the presence of HSV-1 or HSV-2 antibodies on the basis of the relative strength of reactivity against crude antigen preparations from HSV-1 versus HSV-2. This approach results in highly inaccurate inferences of HSV antibody type (Table2). When we tested three commercial enzyme immunoassay kits from Sigma Diagnostics (St. Louis, Mo.), Whittaker Bioproducts (Walkersville, Md.), and Incstar Corp. (Stillwater, Minn.) on sera from patients with culture-documented first episode infections of 3 to 8 weeks duration, only 33 to 55% of subjects were correctly identified (2). Between 38 and 48% of these patients would have been given a diagnosis of the wrong virus type. The remaining inaccurate results were due to lack of sensitivity of the tests.

View this table:
  • View inline
  • View popup
Table 2.

Performance of a commercial EIA for symptomatic genital herpesa

For screening purposes, these tests did no better. When the three kits were tested on sera from subjects with subclinical infections, serum antibodies were correctly identified in as few as 5% of HSV-1-seropositive subjects and in only 55 to 75% of those with HSV-2 infections (2). The most consistent problem was in identifying HSV-2 antibodies from patients with prior HSV-1 infections. Because such patients have anamnestic responses to the type common antigens presented by the new HSV-2 infection, the test becomes more strongly reactive against HSV-1. As a result, only one HSV-2 seroconversion was detected in 12 individuals with culture-documented nonprimary HSV-2 in this study (2).

Type-Specific Antibody TestsAccurate type-specific serologic assays allow identification of silent carriers of HSV-2 infection in patients with or without pre-existing antibodies to HSV-1. Such tests can also provide useful information in symptomatic patients when virological tests such as culture, antigen detection or PCR are not helpful. A number of test formats have been developed to detect type-specific antibodies (5). It is hoped that in the near future truly type-specific tests will supplant those based on crude antigen preparations.

Western blotting.The Western blot assay for HSV was developed more than 10 years ago, and its performance characteristics were validated against culture in symptomatic patients in the United States and Australia (13, 36, 37). When combined with a step to cross-adsorb antibodies to HSV-1 and HSV-2 antigens, the test is highly accurate in differentiating HSV-1 and HSV-2 antibodies, even in HSV-2 patients with previous HSV-1 infections. However, Western blotting is expensive to perform and requires 2 to 5 days for screening and confirmation by preadsorption. For these reasons, this test has not been developed for commercial distribution.

Tests based on gG.A number of investigators have developed tests based on the type-specific protein glycoprotein G from HSV-2 (gG-2) and either glycoprotein C (gC-1) or glycoprotein G (gG-1) from HSV-1. Very limited sequence homology exists between gG-1 and gG-2. Type common sequences are found primarily in the leader sequence, which is lost during processing of the proteins after translation, and in the membrane anchor region, which has limited immunogenicity due to its being sequestered in the infected cell membrane (51, 63).

These tests use a variety of formats for immobilizing the gG antigen, including nitrocellulose (48, 49, 60, 67), capture antibodies (35, 77), and plastic microwells (36, 57). While most of these tests use colorimetric end points based on enzyme-substrate reactions (enzyme immunoassays [EIA]), some that involve radioactive (71) or fluorescent (14) signals have also been described. A type-specific monoclonal antibody-blocking assay with native, crude antigen preparations (including gG-2) performed well against Western blotting in clinically characterized cases (71). The specificity of this test is conferred by the monoclonal antibodies whose binding is (or is not) blocked by the test sample.

Another approach to the identification of type-specific antibodies is to apply recombinant gG-1 and gG-2 from a mammalian expression system to nitrocellulose as discrete bands. This strip immunoblot assay developed by Chiron (Emeryville, Calif.) includes bands of the type-common protein gD-2 and an HSV-1 dominant peptide of glycoprotein gB-1. These two proteins elicit early antibody responses and may allow recognition of early seroconversion before gG antibodies are detectable. The resulting assay was tested against Western blotting and was shown to be 95% sensitive for HSV-1 and 98% sensitive for HSV-2 with 99% specificity for both HSV-1 and HSV-2 (4).

Commercial gG-based type-specific tests.A recently developed gG EIA (Gull Laboratories, Salt Lake City, Utah) may be approved by the Food and Drug Administration (FDA) and on the market in the United States in 1999. This test is based on native gG-1 and gG-2 proteins which have been immunoaffinity purified with monoclonal antibodies. We compared its performance against the Western blot assay on 193 sera submitted to our laboratory for type-specific HSV serologic testing (8). For 172 serum samples which had unequivocal typing results by both assays, the sensitivity of the gG EIA was 95% for HSV-1 and the specificity was 96%; the sensitivity for HSV-2 was 98%, and the specificity was 97%.

Of the 193 serum samples, 13 (7%) had equivocal gG EIA results for HSV-1 or HSV-2. Twelve (2%) of these sera had definitive typing results by Western blotting. Like most EIA formats, the Gull test is rapid (1.5 h) and easy to perform and can be run on any commercially available EIA processor. This test represents a great improvement in accuracy over current EIA tests based on crude antigen preparations. When combined with a second confirmatory test such as Western blotting, the overall sensitivity and specificity approach those of Western blotting.

A second test based on gG-2 that has been purified by lectin chromatography was developed by Diagnology Ltd. (Belfast, Northern Ireland). This test is designed to be performed in a few minutes in clinic or office settings and has been submitted for FDA approval.

Limitations of gG-based tests.Tests based on recombinant gG from bacterial or baculovirus expression vectors (60, 67) may not detect all the antibodies elicited in humans by exposure to gG. Recombinant gG may lack epitopes that depend upon glycosylation mechanisms available in mammalian cells. Lectin- or immunoaffinity-purified gG is likely to provide a more complete complement of conformational and linear epitopes, and, indeed, tests involving native gG-1 and gG-2 have performed well in terms of sensitivity and specificity for HSV-2 antibodies (6, 48, 49, 59, 78).

Any test based on antibodies to only one protein is vulnerable to variations in the titer and timing of antibody responses to that protein. By radioimmunoprecipitation (50) and by Western blotting (1), we have shown that antibody to gG arises relatively late, first appearing 2 to 3 months after infection in 60 to 70% of newly infected patients (Fig. 1). The remaining patients can require up to 6 months to seroconvert to gG. Recent studies with a gG capture EIA (35) and with the Gull gG EIA have confirmed the longer times required for detectable immunoglobulin G (IgG) antibodies to gG to develop. The use of IgM tests may decrease the time needed to detect seroconversion (5, 36, 37).

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Profile of the development of antibodies to HSV-2. Eighteen patients with primary genital HSV-2 were monitored weekly for 8 weeks and then monthly for 12 to 18 months. Sera drawn at these visits were tested, as sets, following adsorption against HSV-1 proteins. Antibodies reacting with HSV-2 proteins were detected by Western blotting. HSV-2 targets of type-specific antibodies were identified by migration characteristics. The cumulative percentage of patients with antibodies (Ab) to glycoproteins gB, gG, and gD, to nucleocapsid proteins VP5 and ICP-35, and to the tegument protein, VP16, were determined for each period (Days) following the onset of genital herpes.

Because of the greater number of antigens available, Western blotting may identify seroconversion more quickly (Fig.2). In a recent clinical trial, the Chiron strip immunoassay identified approximately 4% of sera that lacked antibody to gG but were reactive against gB and/or gD on the strip (unpublished observation). While it is not known whether these results were due to early seroconversion, the results suggest that inclusion of an early-antibody target may increase the sensitivity of protein-specific tests. In our laboratory, a follow-up Western blot can be used to definitively characterize sera with questionable EIA results (8). Type-specific IgM tests may also be helpful in identifying early seroconversion; such tests are in development.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Cumulative seroconversion as shown by Western blotting. Patients with culture-documented first episodes of genital herpes were samples sequentially; 26 were seronegative at the onset of symptoms; of these, 8 had HSV-1 genital herpes (HSV-1 Primary) and 18 had HSV-2 genital herpes (HSV-2 Primary). Twelve were HSV-1 seropositive at onset and had HSV-2 cultured from lesions (HSV-2 Non-primary). The earliest time (Month Post-Infection) at which seroconversion was detected by Western blotting was recorded. The cumulative proportion of patients diagnosed (% Diagnosis) is presented for each period.

RECOMMENDATIONS FOR HSV SEROLOGIC TESTING

Symptomatic PatientsPatients presenting with genital lesions should have samples taken for viral culture or antigen detection (3). This direct testing should always be considered the first choice to definitively establish HSV as the etiologic agent. Typing of HSV isolates from genital lesions should be requested because the natural histories of HSV-1 and HSV-2 differ. However, because virologic tests can be falsely negative when cultures are improperly handled or in patients seen late in the course of primary or nonprimary first episodes, the use of acute- and convalescent-phase sera (best drawn 3 to 4 months later) may be helpful in documenting the acquisition of genital HSV infection. Serologic tests on paired samples alone, is a reasonable backup test when sampling for viral detection is not feasible. While rising titers obtained from nontyping tests may be associated with seroconversion, it is highly recommended that type-specific testing be used if available.

Apparent first episodes of genital symptoms may be, in fact, the first recognized recurrence of a long-standing infection. In our clinic, of more than 200 persons seeking care for first episodes, 5% with HSV-1 and 17% with HSV-2 genital herpes had full Western blot profiles of antibodies to the same type of HSV as was isolated from the genital tract. Rising antibody titers will not be seen in association with such episodes.

Since type-specific serologic test have not been widely used, studies to determine the populations which would most benefit from the identification of HSV serologic status have not been done or are under way. However, the epidemiology and biology of HSV-2 suggest that it may be possible to identify persons at highest risk for serious sequelae of genital herpes. In our opinion, they include asymptomatic patients, patients at risk of HIV infection, and pregnant women. These groups are discussed below.

Asymptomatic PatientsThe most significant potential application of serology is to detect silent carriers of HSV-2, especially in high-risk settings such as STD clinics. Screening of semen donors may also be indicated (56). Tests which detect antibodies to type-specific proteins such as gG should be used; those based on crude antigen preparations are too inaccurate to be helpful in most settings. An exception is that nontyping serologic tests are adequate to screen persons who may be undergoing immunosuppressive therapy for organ transplantation or cancer and who may be candidates for antiviral suppressive therapy, regardless of the type and site of HSV infection.

Patients at Risk of HIV InfectionPatients presenting to STD clinics and homosexual men are at higher than normal risk of having genital herpes. Identification of unrecognized HSV-2 infections by type-specific serologic testing may allow these individuals to practice behavioral change to prevent the transmission of HSV-2. The higher risk of acquiring HIV-1 in those with genital herpes suggests that HSV serologic screening may be important in preventing the spread of this infection as well.

Pregnant WomenType-specific HSV serologic screening has been recommended to identify women at risk of acquiring genital HSV-1 or HSV-2 infections close to term, a setting in which there is high risk (30 to 50%) of neonatal herpes (17, 19, 62). Once rapid, commercial, type-specific tests such gG EIA are widely available, universal screening of pregnant women will become more practical and may be implemented in some settings. Women found to lack HSV-1 or HSV-2 antibodies can be advised of the risks of acquiring genital herpes during late pregnancy and can be provided with focused counseling on behaviors to avoid. In a recent large study of pregnant women, 2.3% of seronegative women seroconverted to HSV-1 and another 1.4% seroconverted to HSV-2 during pregnancy (19). Women whose partners are also tested have the added advantage of understanding the extent of their risk of acquiring genital herpes. The attack rate in HSV-seronegative women with HSV-2-positive partners is 33% over the course of pregnancy, whereas the HSV-1-positive women with an HSV-2-positive partner has a 5% chance of acquiring HSV-2 during pregnancy. The seronegative woman with an HSV-1-positive partner has a 4% chance of acquiring HSV-1; however, not all of these infections are genital (19).

CONCLUSIONS

In conclusion, commercial vendors are developing tests that identify HSV-1 and HSV-2 antibodies from patients with established infections. These tests are considerably more accurate than the kits now on the market. For the next few years, it is likely that the current nontyping tests will remain available. Clinicians and laboratories will have to be especially vigilant to ensure that tests purporting to identify type-specific HSV antibodies are, in fact, based on type-specific proteins or peptide constructs. With that proviso, the widespread availability of low-cost, accurate, type-specific serologic tests may allow the diagnosis of subclinical and unrecognized HSV-2 infections. While serologic diagnosis alone cannot halt the spread of genital herpes, it is an important step in the clinical management and counselling of patients who wish to have full information about the status of their sexual health (29).

  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Ashley R.,
    2. Mack K.,
    3. Critchlow C.,
    4. Shurtleff M.,
    5. Corey L.
    Differential effect of systemic acyclovir treatment of genital HSV-2 infections on antibody responses to individual HSV-2 proteins. J. Med. Virol. 24 1988 309 320
    OpenUrlPubMed
  2. 2.↵
    1. Ashley R.,
    2. Cent A.,
    3. Maggs V.,
    4. Nahmias A.,
    5. Corey L.
    Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 or 2. Ann. Intern. Med. 115 1991 520 526
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Ashley R.
    Laboratory techniques in the diagnosis of herpes simplex infection. Genitourin. Med. 69 1993 174 183
    OpenUrlPubMedWeb of Science
  4. 4.↵
    1. Ashley R.,
    2. Warford A.,
    3. Gleaves C.,
    4. Zenilman J.,
    5. Alexander D.,
    6. Corey L.
    Evaluation of CHIRON RIBA HSV type-1/type-2 strip immunoblot assay for typing of HSV antibodies, abstr. 29 Abstracts of the 35th Annual Meeting of the Infectious Disease Society of America 1997 1997 360
  5. 5.↵
    1. Ashley R.
    Type-specific antibodies to HSV-1 and -2: review of methodology. Herpes 5 1998 33 38
    OpenUrl
  6. 6.↵
    1. Ashley R. L.,
    2. Militoni J.,
    3. Lee F.,
    4. Nahmias A.,
    5. Corey L.
    Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J. Clin. Microbiol. 26 1988 662 667
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Ashley R. L.
    Current concepts of laboratory diagnosis of herpes simplex infection Clinical management of herpes viruses. Sacks S. L., Straus S. E., Whitley R. J., Griffiths P. D. 1995 137 171 IOS Press Washington, D.C
  8. 8.↵
    1. Ashley R. L.,
    2. Wu L.,
    3. Pickering J.,
    4. Tu M.,
    5. Schnorenberg L.
    Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J. Clin. Microbiol. 36 1998 294 295
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Barton S. E.,
    2. Wright L. K.,
    3. Link C. M.,
    4. Munday P. E.
    Screening to detect asymptomatic shedding of herpes simplex virus (HSV) in women with recurrent genital HSV infection. Genitourin. Med. 62 1986 181 185
    OpenUrlPubMedWeb of Science
  10. 10.↵
    1. Barton S. E.,
    2. Davis J. M.,
    3. Moss V. W.,
    4. Tyms A. S.,
    5. Munday P. E.
    Asymptomatic shedding and subsequent transmission of genital herpes simplex virus. Genitourin. Med. 63 1987 102 105
    OpenUrlPubMedWeb of Science
  11. 11.↵
    1. Barton S. E.,
    2. Munday P. E.,
    3. Patel R. J.
    Asymptomatic shedding of herpes simplex virus from the genital tract: uncertainly and its consequences for patient management. Intern. J. Sex. Transm. Dis. AIDS 7 1996 229 232
    OpenUrl
  12. 12.↵
    1. Benedetti J.,
    2. Corey L.,
    3. Ashley R.
    Recurrence rates of genital herpes after symptomatic first-episode infection. Ann. Intern. Med. 121 1994 847 854
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Bernstein D. I.,
    2. Lovett M. A.,
    3. Bryson Y. J.
    Serologic analysis of first-episode nonprimary genital herpes simplex virus infection. Am. J. Med. 77 1984 1055 1060
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Boucher F. D.,
    2. Yasukawa L. L.,
    3. Kerns K.,
    4. Kastelein M.,
    5. Arvin A. M.,
    6. Prober C. G.
    Detection of antibodies to herpes simplex virus type 2 with a mammalian cell line expressing glycoprotein gG-2. Clin. Diagn. Virol. 1 1993 29 38
    OpenUrlPubMed
  15. 15.↵
    1. Breinig M. K.,
    2. Kingsley L. A.,
    3. Armstrong J. A.,
    4. Freeman D. J.,
    5. Ho M.
    Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J. Infect. Dis. 162 1990 299 305
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Brock B. V.,
    2. Selke S.,
    3. Ashley R. L.,
    4. Corey L.
    Frequency of asymptomatic shedding of HSV in women with genital herpes. JAMA 263 1990 418 420
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Brown Z. A.,
    2. Benedetti J.,
    3. Ashley R.,
    4. Burchett S.,
    5. Selke S.,
    6. Berry S.,
    7. Vontver L. A.,
    8. Corey L.
    Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N. Engl. J. Med. 324 1991 1247 1252
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Brown Z. A.,
    2. Benedetti J. K.,
    3. Watts D. H.,
    4. Selke S.,
    5. Berry S.,
    6. Ashley R.,
    7. Corey L.
    A comparison between detailed and simple histories in the diagnosis of genital herpes complicating pregnancy. Am. J. Obstet. Gynecol. 172 1995 1299 1303
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Brown Z. A.,
    2. Selke S.,
    3. Zeh J.,
    4. Kopelman J.,
    5. Maslow A.,
    6. Ashley R. L.,
    7. Watts D. H.,
    8. Berry S.,
    9. Herd M.,
    10. Corey L.
    The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. 337 1997 509 515
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Catotti D. N.,
    2. Clarke P.,
    3. Catoe K. E.
    Herpes revisited: still a cause for concern. Sex. Transm. Dis. 20 1993 77 80
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Christenson B.,
    2. Bottiger M.,
    3. Svensson A.,
    4. Jeansson S.
    A 15-year surveillance study of antibodies to herpes simplex virus types 1 and 2 in a cohort of young girls. J. Infect. 25 1992 147 154
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Corey L.
    Genital herpes Sexually transmitted diseases 2nd ed. Holmes K. K., Mardh P. A., Sparling P. F., Wiesner P. J. 1990 391 413 McGraw Hill Book Co. New York, N.Y
  23. 23.↵
    Corey, L. 1994. The current trend in genital herpes. Progress in prevention. Sex. Transm. Dis. 21(Suppl. 2):S38–S44.
  24. 24.↵
    1. Corey L.,
    2. Holmes K. K.
    Genital herpes simplex virus infection: current concepts in diagnosis, therapy and prevention. Ann. Intern. Med. 98 1983 973 983
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Corey L.,
    2. Wald A.
    New developments in the biology of genital herpes Clinical management of herpes viruses Sacks S. L., Straus S. E., Whitley R. J., Griffiths P. D. 1995 43 53 IOS Press New York, N.Y
  26. 26.↵
    1. Cowan F. M.,
    2. Johnson A. M.,
    3. Ashley R.,
    4. Corey L.,
    5. Mindel A.
    Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. J. Infect. Dis. 174 1996 470 475
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Cunningham A. L.,
    2. Lee F. K.,
    3. Ho D. W.,
    4. Field P. R.,
    5. Law C. L. H.,
    6. Packham D. R.,
    7. McCrossin I. D.,
    8. Sjogren-Jansson E.,
    9. Jeansson S.,
    10. Nahmias A. J.
    Herpes simplex virus type 2 antibody in patients attending antenatal or STD clinics. Med. J. Aust. 158 1993 525 528
    OpenUrlPubMedWeb of Science
  28. 28.↵
    1. Douglas J. M.,
    2. Critchlow C.,
    3. Benedetti J.,
    4. Mertz G. J.,
    5. Connor J. D.,
    6. Hintz M. A.,
    7. Fahnlander A.,
    8. Remington M.,
    9. Winter C.,
    10. Corey L.
    A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med. 310 1984 1551 1556
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Fairley I.,
    2. Monteiro E. F.
    Patient attitudes to type-specific serological tests in the diagnosis of genital herpes. Genitourin. Med. 73 1997 259 262
    OpenUrlPubMedWeb of Science
  30. 30.↵
    1. Fleming D. T.,
    2. McQuillan G. M.,
    3. Johnson R. E.,
    4. Nahmias A. J.,
    5. Aral S. O.,
    6. Lee F. K.,
    7. St. Louis M. E.
    Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337 1997 1105 1111
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Forsgren M.,
    2. Skoog E.,
    3. Jeansson S.,
    4. Olofsson S.,
    5. Giesecke J.
    Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969, 1983 and 1989: implications for STD epidemiology. Int. J. Sex. Transm. Dis. AIDS 5 1994 113 116
    OpenUrl
  32. 32.↵
    1. Frenkel L. M.,
    2. Garratty E. M.,
    3. Shen J. P.,
    4. Wheeler N.,
    5. Clark O.,
    6. Bryson Y. J.
    Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann. Intern. Med. 118 1993 414 418
    OpenUrlPubMedWeb of Science
  33. 33.↵
    1. Gibson J. J.,
    2. Hornung C. A.,
    3. Alexander G. R.,
    4. Lee F. K.,
    5. Potts W. A.,
    6. Nahmias A. J.
    A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J. Infect. Dis. 162 1990 306 312
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Green J.,
    2. Kocsis A.
    Psychological factors in recurrent genital herpes. Genitourin. Med. 73 1997 253 258
    OpenUrlPubMedWeb of Science
  35. 35.↵
    1. Hashido M.,
    2. Lee F. K.,
    3. Inouye S.,
    4. Kawana T.
    Detection of herpes simplex virus type-specific antibodies by an enzyme-linked immunosorbent assay based on glycoprotein G. J. Med. Virol. 53 1997 319 323
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Ho D. W. T.,
    2. Field P. R.,
    3. Sjogren-Jansson E.,
    4. Jeansson S.,
    5. Cunningham A. L.
    Indirect ELISA for the detection of HSV-2 specific IgG and IgM antibodies with glycoprotein G (gG-2). J. Virol. Methods 36 1992 249 264
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Ho D. W. T.,
    2. Field P. R.,
    3. Irving W. L.,
    4. Packham D. R.,
    5. Cunningham A. L.
    Detection of immunoglobulin M antibodies to glycoprotein G-2 by Western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. J. Clin. Microbiol. 31 1993 3157 3164
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Holmberg S. D.,
    2. Stewart J. A.,
    3. Russel G.,
    4. Byers R. H.,
    5. Lee F. K.,
    6. O’Malley P. M.,
    7. Nahmias A. J.
    Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 259 1988 1048 1050
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Hook E. W.,
    2. Cannon R. O.,
    3. Nahmias A. J.,
    4. Lee F. F.,
    5. Campbell C. H.,
    6. Glasser D.,
    7. Quinn T. C.
    Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J. Infect. Dis. 165 1992 251 255
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Johnson L. S.,
    2. Polsky B.
    Herpes simplex virus infection in the cancer patient. Infect. Med. 10 1993 18 52
    OpenUrl
  41. 41.↵
    1. Johnson J. R.,
    2. Egaas S.,
    3. Gleaves C. A.,
    4. Hackman R.,
    5. Bowden R. A.
    Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin. Infect. Dis. 14 1992 38 45
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Koelle D. N.,
    2. Benedetti J.,
    3. Langenberg A.,
    4. Corey L.
    Asymptomatic reactivation of herpes simplex virus in women after first episode of genital herpes. Ann. Intern. Med. 116 1992 433 437
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Koutsky L.,
    2. Ashley R.,
    3. Homes K.,
    4. Stevens C.,
    5. Critchlow C.,
    6. Kiviat N.,
    7. Lipinski C.,
    8. Wolner-Hanssen P.,
    9. Corey L.
    The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex. Transm. Dis. 17 1990 90 94
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Koutsky L. A.,
    2. Stevens C. E.,
    3. Holmes K. K.,
    4. Ashley R. L.,
    5. Kiviat N. B.,
    6. Critchlow C. W.,
    7. Corey L.
    Underdiagnosis of genital herpes by current clinical and viral isolation procedures. N. Engl. J. Med. 326 1992 1533 1539
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Kusne S.,
    2. Schwartz M.,
    3. Breinig M.,
    4. Dummer J. S.,
    5. Lee R. E.,
    6. Selby R.,
    7. Starzl T. E.,
    8. Simmons R. L.,
    9. Ho M.
    Herpes simplex virus hepatitis after solid organ transplantation in adults. J. Infect. Dis. 163 1991 1001 1007
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Lafferty W. E.,
    2. Krofft S.,
    3. Remington M.,
    4. Giddings R.,
    5. Winter C.,
    6. Cent A.,
    7. Corey L.
    Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high prevalence population. J. Clin. Microbiol. 25 1987 323 326
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Langenberg A.,
    2. Benedetti J.,
    3. Jenkins J.,
    4. Ashley R. L.,
    5. Winter C.,
    6. Corey L.
    Development of clinically recognizable genital lesions among women previously identified as having “asymptomatic” herpes simplex virus type 2 infection. Ann. Intern. Med. 110 1989 882 887
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Lee F. K.,
    2. Coleman R. M.,
    3. Pereira L.,
    4. Bailey P. D.,
    5. Tatsuno M.,
    6. Nahmias A. J.
    Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J. Clin. Microbiol. 22 1985 641 644
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Lee F. K.,
    2. Pereira L.,
    3. Griffin C.,
    4. Reid E.,
    5. Nahmias A.
    A novel glycoprotein for detection of herpes simplex virus type 1-specific antibodies. J. Virol. Methods 14 1986 111 118
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Lopez C.,
    2. Arvin A.,
    3. Ashley R.
    Immunity to herpesvirus infection in humans The human herpesviruses. Roizman B., Whitley R. J., Lopez C. 1993 397 425 Raven Press New York, N.Y
  51. 51.↵
    1. McGeoch D. J.,
    2. Moss H. W.,
    3. McNab D.,
    4. Frame M. C.
    DNA sequence and genetic content of the HindIII region in the short unique component of herpes simplex virus type 2 genome: identification of the gene encoding glycoprotein G, and evolutionary comparisons. J. Gen. Virol. 68 1987 19 38
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Mertz G.,
    2. Schmidt O.,
    3. Jourden J. L.,
    4. Guinan M. E.,
    5. Remington M. L.,
    6. Fahnlander A.,
    7. Winter C.,
    8. Holmes K. K.,
    9. Corey L.
    Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex. Transm. Dis. 12 1985 33 39
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    1. Mertz G.,
    2. Benedetti J.,
    3. Ashley R.,
    4. Selke S.,
    5. Corey L.
    Risk factors for sexual transmission of genital herpes. Ann. Intern. Med. 116 1992 197 202
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    1. Mertz G.,
    2. Loveless M. O.,
    3. Levin M. J.,
    4. Kraus S. J.,
    5. Fowler S. L.,
    6. Goade D.,
    7. Trying S. K.
    Oral famciclovir for suppression of recurrent genital herpes simplex virus in women: a multicenter double-blind placebo controlled trial. Arch. Intern. Med. 157 1997 343 349
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Mindel A.,
    2. Faherty A.,
    3. Carney O.,
    4. Patou G.,
    5. Freris M.,
    6. Williams P.
    Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet ii 1988 926 928
    OpenUrl
  56. 56.↵
    1. Moore D. E.,
    2. Ashley R. L.,
    3. Zarutskie P. W.,
    4. Coombs R.,
    5. Soules M. R.,
    6. Corey L.
    Transmission of genital herpes by artificial insemination with a donor experiencing asymptomatic primary HSV-2 infection. JAMA 261 1989 3441 3443
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Nahmias A. J.,
    2. Lee F. K.,
    3. Keyserling H. L.
    The epidemiology of genital herpes Genital and neonatal herpes. Stanberry L. 1996 93 108 John Wiley & Sons, Inc. New York, N.Y
  58. 58.↵
    1. Oliver L.,
    2. Wald A.,
    3. Kim M.,
    4. Zeh J.,
    5. Selke S.,
    6. Ashley R.,
    7. Corey L.
    Seroprevalence of herpes simplex virus infections in a family medicine clinic. Arch. Fam. Med. 4 1995 228 232
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Olofsson S.,
    2. Lundstrom M.,
    3. Marsden H.,
    4. Jeansson S.,
    5. Vahine A.
    Characterization of a herpes simplex virus type 2-specified glycoprotein with affinity for N-acetylgalactosamine-specific lectins and its identification as g92K or gG. J. Gen. Virol. 67 1986 737 744
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Parks D. L.,
    2. Smith C. M.,
    3. Rose J. M.,
    4. Brandis J.,
    5. Coates S. R.
    Seroreactive recombinant herpes simplex virus type 2-specific glycoprotein G. J. Clin. Microbiol. 29 1991 778 781
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Patel R.,
    2. Bodsworth N. J.,
    3. Woolley P.,
    4. Peters B.,
    5. Vejlsgaard G.,
    6. Saari S.,
    7. Gibb A.,
    8. Robinson J.,
    9. the International Valaciclovir HSV Study Group
    Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin. Med. 73 1997 105 109
    OpenUrlPubMedWeb of Science
  62. 62.↵
    1. Prober C. G.,
    2. Corey L.,
    3. Brown Z. A.,
    4. Hensleigh P. A.,
    5. Frenkel L. M.,
    6. Bryson Y. J.,
    7. Whitley R. J.,
    8. Arvin A. M.
    The management of pregnancies complicated by genital infections with herpes simplex virus. Clin. Infect. Dis. 15 1992 1031 1038
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    1. Rapoport T. A.
    Protein translocation across and integration into membranes. Crit. Rev. Biochem. 20 1986 73 137
    OpenUrlPubMed
  64. 64.↵
    1. Rattray M. C.,
    2. Corey L.,
    3. Reeves W. C.,
    4. Vontver L. A.,
    5. Holmes K. K.
    Recurrent genital herpes among women: symptomatic vs asymptomatic viral shedding. Br. J. Vener. Dis. 54 1978 262 265
    OpenUrlPubMedWeb of Science
  65. 65.↵
    1. Ross J. D. C.,
    2. Smith J. W.,
    3. Elton R. A.
    The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978–1991. Genitourin. Med. 69 1993 381 383
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    Safrin, S. 1992. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. J. Acquired Immune Defic. Syndr. 5(Suppl. 1):S29–S32.
  67. 67.↵
    1. Sanchez-Martinez D.,
    2. Schmid D. S.,
    3. Whittington W.,
    4. Brown D.,
    5. Reeves W. C.,
    6. Chatterjee S.,
    7. Whitley R. J.,
    8. Pellet P. E.
    Evaluation of a test based on baculovirus-expressed glycoprotein G for detection of herpes simplex virus type-specific antibodies. J. Infect. Dis. 164 1991 1196 1199
    OpenUrlPubMedWeb of Science
  68. 68.↵
    1. Schacker T.,
    2. Ryncarz A.,
    3. Goddard J.,
    4. Diem K.,
    5. Shaughnessy M.,
    6. Corey L.
    Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280 1998 61 66
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    Schacker, T., J. Zeh, H.-L. Hu, E. L. Hill, and L. Corey. Frequency of symptomatic and asymptomatic HSV-2 reactivations among HIV-infected men. J. Infect. Dis., in press.
  70. 70.↵
    1. Scoular A.,
    2. Leask B. G. S.,
    3. Carrington D.
    Changing trends in genital herpes due to herpes simplex virus type 1 in Glasgow, 1985–88. Genitourin. Med. 66 1990 226
    OpenUrlPubMedWeb of Science
  71. 71.↵
    1. Slomka M. J.,
    2. Ashley R. L.,
    3. Cowan R. M.,
    4. Cross A.,
    5. Brown D. W. G.
    Monoclonal antibody blocking testes for the detection of HSV-1 and HSV-2 specific humoral responses: comparison with Western blot assay. J. Virol. Methods 55 1995 27 35
    OpenUrlCrossRefPubMedWeb of Science
  72. 72.↵
    1. Stamm W. E.,
    2. Handsfield H. H.,
    3. Rompalo A. M.,
    4. Ashley R.,
    5. Roberts P.,
    6. Corey L.
    The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 260 1988 1429 1433
    OpenUrlCrossRefPubMedWeb of Science
  73. 73.↵
    1. Stewart J. A.,
    2. Reef S. E.,
    3. Pellett P. E.,
    4. Corey L.,
    5. Whitley R. J.
    Herpesvirus infections in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 21 1995 S114 S120
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Strand A.,
    2. Vahlne A.,
    3. Svennerholm B.,
    4. Wallin J.,
    5. Lycke E.
    Asymptomatic virus shedding in men with genital herpes infection. Scand. J. Infect. Dis. 18 1986 195 197
    OpenUrlPubMedWeb of Science
  75. 75.↵
    1. Straus S. E.,
    2. Takiff H. E.,
    3. Seidlin M.,
    4. Bachrach S.,
    5. Lininger L.,
    6. DiGiovanna J. J.
    Suppression of frequently recurring genital herpes. N. Engl. J. Med. 310 1984 1545 1550
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    1. Straus S. E.,
    2. Seidlin M.,
    3. Takiff H. E.,
    4. Rooney J. F.,
    5. Felser J. M.,
    6. Smith H. A.,
    7. Roane P.,
    8. Johnson F.,
    9. Hallahan C.,
    10. Ostrove J. M.,
    11. Nusinoff-Lehrman S.
    Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpes. Sex. Transm. Dis. 16 1989 107 113
    OpenUrlCrossRefPubMedWeb of Science
  77. 77.↵
    1. Sullender W. M.,
    2. Yasukawa L. L.,
    3. Schwartz M.,
    4. Pereira L.,
    5. Hensleigh P. A.,
    6. Prober C. G.,
    7. Arvin A. M.
    Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. J. Infect. Dis. 157 1988 164 171
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Svennerholm B.,
    2. Olofsson S.,
    3. Jeansson S.,
    4. Vahlne A.,
    5. Lycke E.
    Herpes simplex virus type-selective enzyme-linked immunosorbent assay with Helix pomatia lectin-purified antigens. J. Clin. Microbiol. 19 1984 235 239
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Wald A.,
    2. Zeh J.,
    3. Selke S.,
    4. Ashley R. L.,
    5. Corey L.
    Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med. 333 1995 770 775
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.↵
    1. Wald A.,
    2. Taylor L.,
    3. Warren T.,
    4. Remington M.,
    5. Selke S.,
    6. Zeh J.,
    7. Corey L.
    Subclinical shedding of herpes simplex virus in men with genital herpes, abstr. H-111 Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995 199 American Society for Microbiology Washington, D.C
  81. 81.↵
    1. Wald A.,
    2. Zeh J.,
    3. Barnum G.,
    4. Davis L. G.,
    5. Corey L.
    Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. 124 1996 8 15
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    1. Wald A.,
    2. Koutsky L.,
    3. Ashley R. L.,
    4. Corey L.
    Genital herpes in a primary care clinic: demographic and sexual correlates of herpes simplex type 2 infections. Sex. Transm. Dis. 24 1997 149 155
    OpenUrlPubMedWeb of Science
  83. 83.↵
    1. Wald A.,
    2. Corey L.,
    3. Cone R.,
    4. Hobson A.,
    5. Davis G.,
    6. Zeh J.
    Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J. Clin. Invest. 99 1997 1092 1097
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.↵
    1. Whitley R. J.
    Perinatal herpes simplex virus infections. Rev. Med. Virol. 1 1991 101 110
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology
Rhoda L. Ashley, Anna Wald
Clinical Microbiology Reviews Jan 1999, 12 (1) 1-8; DOI: 10.1128/CMR.12.1.1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Clinical Microbiology Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology
(Your Name) has forwarded a page to you from Clinical Microbiology Reviews
(Your Name) thought you would be interested in this article in Clinical Microbiology Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology
Rhoda L. Ashley, Anna Wald
Clinical Microbiology Reviews Jan 1999, 12 (1) 1-8; DOI: 10.1128/CMR.12.1.1
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • SUMMARY
    • EPIDEMIOLOGY OF GENITAL HERPES
    • CLINICAL IMPACT OF GENITAL HERPES
    • CORRELATES OF GENITAL HERPES INFECTIONS
    • ROLE OF UNDIAGNOSED INFECTION AND SUBCLINICAL HSV SHEDDING IN THE HERPES EPIDEMIC
    • DIAGNOSIS OF SYMPTOMATIC GENITAL HERPES
    • RECOMMENDATIONS FOR HSV SEROLOGIC TESTING
    • CONCLUSIONS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Disease Outbreaks
Herpes Genitalis
Herpesvirus 2, Human

Related Articles

Cited By...

About

  • About CMR
  • Editor in Chief
  • Editorial Board
  • Policies
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Ethics
  • Contact Us

Follow #ClinMicroRev

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0893-8512; Online ISSN: 1098-6618